Keywords
antibiotic resistance
Escherichia coli
Abstract
Urinary tract infection (UTI) is one of the most common types of infection in both hospitalized and outpatient settings. The etiology is mostly bacterial, and the typical causative agent is uropathogenic Escherichia coli. There is a noticeable increase in drug resistance of pathogenic microorganisms. The aim of the study was retrospective analyses of etiological agents of UTI and their antibiotic resistance patterns in Nephrology Unit patients. Material and methods: An infection was diagnosed based on the patient's symptoms and positive results of urine culture, carried out over 26 months. The clinical material was tested by using the VITEK system, the drug susceptibility of the emerged pathogens was identified. Results: The most common etiological agents of UTI were Gram-negative rods: Escherichia coli (51.23%), Klebsiella spp. (19.3%) and Proteus spp. (13.68%). The analysis of drug resistance profiles of these pathogens showed a high percentage of strains resistant to broad-spectrum penicillins and fluoroquinolones. At the same time, it seems that E. coli isolates presented the most favorable pattern of drug susceptibility in this comparison. Conclusions: The alarming tendency of increasing drug resistance among pathogens causing UTIs to antibiotics such as penicillins or fluoroquinolones prompts a careful choice of drugs in empirical therapies. The most appropriate practice in this regard seems to be meticulous control of nosocomial infections and making therapeutic decisions based on the knowledge of local microbiological data.
References
1. Gupta K, Grigoryan L, Trautner B. Urinary tract infection. Ann Intern Med. 2017;167(7):49-64.
2. Karam MRA, Habibi M, Bouzari S. Urinary tract infection: Pathogenicity, antibiotic resistance and development of effective vaccines against uropathogenic Escherichia coli. Mol Immunol. 2019;108:56-67.
3. Redder JD, Leth RA, Møller JK. Analysing risk factors for urinary tract infection based on automated monitoring of hospital-acquired infection. J Hosp Infect. 2016;92(4):397-400.
4. Foxman B. Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden. Infect Dis Clin. 2014;28(1):1-13.
5. Forsyth VS, Armbruster CE, Smith SN, Pirani A, Springman AC, Walters MS, et al. Rapid growth of uropathogenic Escherichia coli during human urinary tract infection. MBio. 2018;9(2):e00186-18.
6. McLellan LK, Hunstad DA. Urinary tract infection: pathogenesis and outlook. Trends Mol Med. 2016;22(11):946-57.
7. Smelov V, Naber K, Johansen TEB. Improved classification of urinary tract infection: future considerations. Eur Urol Suppl. 2016;15(4):71-80.
8. Mann R, Mediati DG, Duggin IG, Harry EJ, Bottomley AL. Metabolic adaptations of uropathogenic E. coli in the urinary tract. Front Cell Infect Microbiol. 2017;7:241.
9. Gomila A, Shaw E, Carratalà J, Leibovici L, Tebé C, Wiegand I, et al. Predictive factors for multidrug-resistant gram-negative bacteria among hospitalised patients with complicated urinary tract infections. Antimicrobiol Res Infect Control. 2018;7(1):1-11.
10. Mody L, Juthani-Mehta M. Urinary tract infections in older women. JAMA. 2014;311:844-54.
11. Sadowska M. Dowodzenie związku przyczynowo-skutkowego w sprawach o zakażenia szpitalne. Studia Prawnicze KUL. 2017;3:107-20.
12. Ziółko A. Czynniki ryzyka związane z rozpoznawaniem i zapobieganiem zakażeniom szpitalnym. Forum Zakażeń. 2016;7:109-13.
13. Edwardson S, Cairns C. Nosocomial infections in the ICU. Anaesth Intensive Care Med. 2019;20(1):14-8.
14. Khan HA, Baig FK, Mehboob R. Nosocomial infections: Epidemiology, prevention, control and surveillance. Asian Pac J Trop Biomed. 2017;7(5):478-82.
15. Walker E, Lyman A, Gupta K, Mahoney MV, Snyder GM, Hirsch EB. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis. 2016;63(7):960-5.
16. Santajit S, Indrawattana N. Mechanisms of antimicrobial resistance in ESKAPE pathogens. BioMed Res Int. 2016;2475067.
17. Wilson APR, Livermore DM, Otter JA, Warren RE, Jenks P, Enoch DA, et al. Prevention and control of multi-drug-resistant Gram-negative bacteria: recommendations from a Joint Working Party. J Hosp Infect. 2016;92:S1-S44.
18. Paniagua-Contreras GL, Monroy-Pérez E, Rodríguez-Moctezuma JR, Domínguez-Trejo P, Vaca-Paniagua F, Vaca S. Virulence factors, antibiotic resistance phenotypes and O-serogroups of Escherichia coli strains isolated from community-acquired urinary tract infection patients in Mexico. J Microbiol Immunol Infect. 2017;50(4):478-85.
19. Tenney J, Hudson N, Alnifaidy H, Li JTC, Fung, KH. Risk factors for aquiring multidrug-resistant organisms in urinary tract infections: a systematic literature review. Saudi Pharmaceutical J. 2018;26(5):678-84.
20. Li X, Chen Y, Gao W, Ye H, Shen Z, Wen Z, Wei J. A 6-year study of complicated urinary tract infections in southern China: prevalence, antibiotic resistance, clinical and economic outcomes. Ther Clin Risk Manag. 2017;13:1479.
21. Aguinaga A, Gil-Setas A, Alvaro A, García-Irure JJ, Navascués A. Uncomplicated urinary tract infections. Antimicrobial susceptibility study in Navarre. In Anales del Sistema Sanitario de Navarra. 2018;41(1):17-26.
22. Bollestad M, Vik I, Grude N, Blix HS, Brekke H, Lindbaek M. Bacteriology in uncomplicated urinary tract infections in Norwegian general practice from 2001-2015. BJGP Open. 2018;1(4).
23. Karam G, Chastre J, Wilcox MH, Vincent JL. Antibiotic strategies in the era of multidrug resistance. Crit Care. 2016;20(1):1-9.
24. Masajtis-Zagajewska A, Nowicki M. New markers of urinary tract infection. Clin Chim Acta. 2017;471:286-91.
25. Rohde C, Wittmann J, Kutter E. Bacteriophages: A therapy concept against multi-drug – resistant bacteria. Surg Infect. 2018;19(8):737-44.
26. Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017;8(3):162.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 Unported License.
Copyright (c) 2021 Authors